Advertisement
Advertisement
U.S. Markets open in 9 hrs 2 mins
Advertisement
Advertisement
Advertisement
Advertisement

CARsgen Therapeutics Holdings Limited (2171.HK)

HKSE - HKSE Delayed Price. Currency in HKD
Add to watchlist
18.060-0.100 (-0.55%)
As of 11:56AM HKT. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close18.160
Open18.200
Bid17.940 x N/A
Ask18.060 x N/A
Day's Range17.620 - 18.480
52 Week Range9.680 - 57.250
Volume397,000
Avg. Volume1,671,532
Market Cap10.246B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est37.01
  • PR Newswire

    CARsgen Appoints Dr. Hua Jiang as Executive Director

    CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Hua Jiang ("Dr. Jiang") has been appointed as Executive Director of the Company.

  • PR Newswire

    CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022

    CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, the Company presented two posters with study results for CT041, an autologous CAR T-cell product candidate against protein Claudin18.2 (CLDN18.2). The two posters included (1) results from the multicenter Phase 1b CT041 trial in the U

  • PR Newswire

    Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers

    CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the phase I trial interim results of an investigator-initiated trial of CT041 have been published in Nature Medicine (https://www.nature.com/articles/s41591-022-01800-8), which is one of the top international medical journals in the Nature Portfolio (2-year Impact Factor of 53.44).

Advertisement
Advertisement